YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Alphatec ATEC shares ended the last trading session 19.7% higher at $10.58. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 9.3% loss over the pa…
Earnings Call Insights: ClearPoint Neuro (CLPT) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 in itself has been an exciting one and possibly one of the most important series of events in our history," said Joseph Burnett (Presiden…
Mettler-Toledo (MTD) came out with quarterly earnings of $11.46 per share, beating the Zacks Consensus Estimate of $10.78 per share. This compares to earnings of $10.09 per share a year ago. These figures are adjusted for non-recurring ite…
OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items. This qua…
ClearPoint Neuro, Inc. CLPT shares rallied 26% in the last trading session to close at $16.81. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stoc…
(RTTNews) - Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in panc…
DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical dev…
Earnings Call Insights: ClearPoint Neuro (CLPT) Q1 2026 MANAGEMENT VIEW * “Our company has started 2026 on a strong note by achieving record revenue of $12.1 million for the quarter,” and this was “driven primarily by organic devices growt…
Key Points Interested in ClearPoint Neuro, Inc.? Here are five stocks we like better. ClearPoint Neuro reported record first-quarter 2026 revenue of $12.1 million, up 43% year over year, and reaffirmed its full-year revenue outlook of $52…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Daiwa upgraded Qualcomm (QCOM) to Outperfo…
UFP Technologies (UFPT) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $2.47 per share a year ago. These figures are adjusted for non-recurring ite…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Drill Bits Market size & share revenue was valued at approximately USD 316 Mi…
ClearPoint Neuro logo Key Points 2025 revenue rose to $37.0 million (from $31.4M), Q4 revenue was $10.4 million, gross margin held near 61–62%, and the company ended the year with $45.9 million in cash after raising ~$51.4 million from not…
ClearPoint Neuro, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Performance Drivers Management has transitioned the company into a two-phase growth strategy: 'Fast Forward' to penetrate existing $1 billion markets and '…
Earnings Call Insights: ClearPoint Neuro (CLPT) Q4 2025 MANAGEMENT VIEW * CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocri…
The following companies are expected to report earnings after hours on 03/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases. lululemon athletica inc. (LULU)is reporting for the quarter ending January 31, 20…
ClearPoint Neuro, Inc. CLPT, a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, recently received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. This lat…
Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter can be downloaded here. In the quarter, Minot Light generated solid returns for limited partners, with a net of 7.…
(RTTNews) - A cluster of healthcare and med-tech stocks posted notable strength in Monday's after-hours session, driven by regulatory progress, clinical-data visibility, and merger-related developments, with a few quiet movers adding to th…
Deep Sail Capital, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The fund returned 5.8% net of fees in the third quarter, outperforming the Russell 2000 Mid Cap G…
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-re…
TransMedics (TMDX) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items. T…
ClearPoint Neuro CLPT recently unveiled the development of its proprietary Robotic Neuro-Navigation System, a move that positions the company to contribute to robotics, neurosurgery, and advanced drug delivery. By integrating its establish…
(RTTNews) - Several biotech stocks hit new highs during regular trading on Wednesday, with some extending their gains in after-hours trading. While positive trial results in myotonic dystrophy type 1 lifted PepGen in after-hours trading, a…
(RTTNews) - Shares of ClearPoint Neuro Inc. (CLPT) are up nearly 40% at $17 in premarket trading on Wednesday. This global device, cell, and gene therapy-enabling company operates in two segments: (i) a business providing medical devices f…
Earnings Call Insights: ClearPoint Neuro (CLPT) Q2 2025 MANAGEMENT VIEW * Joseph Michael Burnett, CEO, described 2025 as the start of ClearPoint Neuro’s “third phase,” called Fast. Forward., emphasizing an expanded commitment to cell and g…
CLEARPOINT NEURO REPORTS MIXED Q2 2025 RESULTS AMID STRATEGIC EXPANSION CLEARPOINT NEURO INC (NASDAQ:CLPT [https://www.chartmill.com/stock/quote/CLPT]) announced its second-quarter 2025 financial results, delivering record revenue but fall…
Major earnings expected after the bell on Tuesday include: * CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]) * Inovio Pharmaceuticals (INO [https://seekingalpha.com/symbol/INO]) * Luminar Technologies (LAZR [https://seekingalpha.co…
Introduction & Market Context ClearPoint Neuro Inc. (NASDAQ:CLPT) unveiled its corporate presentation on May 13, 2025, highlighting the company’s strategic vision as it enters what management calls the "Fast Forward" phase of its developme…
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha’s Substack. In this article, we will summarize the bulls’ thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June.Is Freseniu…
After uniQure (QURE) provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington’s disease, and said the company has reached alignment with the FDA to support the accelerated approval pathway,…
Brain-computer interface (BCI) technology creates a direct link between the brain’s electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functio…
Growth stocks have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights. Then, rising rates and recession fears brought them crashing back to earth. But I believe the growth stock story is far…
Penny stocks are on the riskier end of the public equity spectrum. They are characterized by their low volume, affordable pricing, and the rapid pace at which their values can surge or plummet compared to more traditional stocks. But, for…
Fifteen bucks won’t go too far these days – unless you want to invest in these under-$15 stocks to buy. Inflation growth may be falling, which obscures the real fact that pricing today for goods and services remains higher than just two ye…